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ABSTRACT Lung surfactant causes the surface tension, g, in the alveoli to drop to nearly zero on exhalation; in the upper
airways g is ;30 mN/m and constant. Hence, a surface tension gradient exists between alveoli and airways that should lead to
surfactant ﬂow out of the alveoli and elimination of the surface tension gradient. However, the lung surfactant speciﬁc protein
SP-C enhances the resistance to surfactant ﬂow by regulating the ratio of solid to ﬂuid phase in the monolayer, leading to
a jamming transition at which the monolayer transforms from ﬂuidlike to solidlike. The accompanying three orders of magnitude
increase in surface viscosity helps minimize surfactant ﬂow to the airways and likely stabilizes the alveoli against collapse.
INTRODUCTION
Lung surfactant is a complex mixture of lipids and proteins
originating from the type II cells that line the alveolar epi-
thelial surfaces of humans and other mammals (1,2). Lung
surfactant reduces the surface tension in the alveolar spaces,
which minimizes the work of breathing, promotes uniform
lung inﬂation, and prevents alveolar collapse during the
cycles of lung expansion and compression. A lack of func-
tional surfactant due to prematurity leads to neonatal respi-
ratory distress syndrome (NRDS; 1,3). Surfactant inhibition
is implicated in the development of acute RDS in infants and
adults (2). Surfactant replacement therapy, typically with ex-
tracts of bovine or porcine lung surfactants, has proven to be
of great clinical value in reducing the effects of NRDS (2,3).
To maintain proper lung function, the surface tension, g,
in the alveoli must drop to nearly zero on exhalation (2,4,5).
In the trachea, g is ;30 mN/m (6) and in the connecting
airways, g is ;15 mN/m (7). As a result, a surface tension
gradient exists among the trachea, airways, and the alveoli
during exhalation. Surface tension gradients induce ﬂow and
the transport of surfactant and other interfacial materials in
the direction of the higher surface tension (8,9), which is
likely necessary to promote removal of particulates and other
debris from the deep lung (2).
For surface tension driven ﬂows in the lungs, the rate of
surfactant transport is proportional to Dg=Reff . Dg is the dif-
ference in surface tension between the alveoli (where surfac-
tant is generated and expressed) and the airways (where no
surfactant is expressed), and Reff is an effective ﬂow re-
sistance that depends on the surface viscosity, hs, of the
surfactant ﬁlm (9), the bulk viscosity of the epithelial lining
ﬂuid, h (10–12), the thickness of the epithelial lining ﬂuid
(9,11,12), and the branching and geometry of the airways,
surface interactions, particulates, etc. (2,13–15). Instillation
of replacement surfactants in premature infants (in which the
higher surface tension is in the alveolus) occurs by surface
tension driven ﬂows in the smaller airways and alveoli and
takes only minutes to occur in practice (10,11). Reversing
the direction of the surface tension gradient in normal lungs
would suggest that the ﬂow of surfactant from the lungs is
just as fast in the absence of a sufﬁciently high ﬂow resis-
tance. Moreover, the total internal area of the terminal
bronchioles is ;3000 cm2, and the total internal area of the
tracheobronchial tree from larynx to terminal bronchioles is
;4000 cm2 (16). By comparison, alveolar surface area is
80–150 m2 or;200–300 times larger. Hence, only a fraction
of the alveolar surfactant could line the whole airway. For
surface tension gradients to be maintained, there must be
a strong resistance to surfactant ﬂow at low surface tension.
One way to enhance the ﬂow resistance would be for the
surface viscosity to increase substantially with decreasing
surface tension (increasing Reff) to offset the increasing sur-
face tension gradient, Dg, during exhalation (15), thereby
keeping Dg=Reff small.
How does lung surfactant make the necessary adjustments
in the two-dimensional surface viscosity as a function of
surface tension? Many of the common mechanisms for en-
hancing solution viscosity in three dimensions, for example,
polymer entanglements, have no analogy in two dimen-
sions. The changes in surface viscosity must accompany the
changes in monolayer phase behavior that occur with de-
creasing surface tension (increasing surface pressure). At
low surface pressures, there are typically ﬂuid phases, with
liquidlike molecular correlations and low surface viscosity
(14,15). As the surface pressure increases to levels expected
in the lungs (.40 mN/m), solid phases, with long-range
molecular correlations, form. Over a wide range of surface
pressure in multicomponent lung surfactant monolayers,
these solid and ﬂuid phases can coexist (13,15,17). We have
found that the surface viscosity at phase coexistence can
Submitted August 30, 2004, and accepted for publication March 2, 2005.
Address reprint requests to Joseph A. Zasadzinski, Tel.: 805-893-4769;
Fax: 805-893-4731; E-mail: gorilla@engineering.ucsb.edu.
 2005 by the Biophysical Society
0006-3495/05/07/266/08 $2.00 doi: 10.1529/biophysj.104.052092
266 Biophysical Journal Volume 89 July 2005 266–273
undergo a dramatic increase due to the jamming of solid
phase domains at a critical surface area fraction (13). Rather
small changes in the solid/ﬂuid phase ratio can lead to large
changes in surface viscosity (13,15). Here we show that the
lung surfactant speciﬁc protein SP-C (18), the function of
which has not yet been fully established, interacts with the
lipids of the monolayer to regulate the surface viscosity. The
SP-C protein manages this by selectively removing ﬂuid
phase lipids from the monolayer at low surface tensions to
form multilayer patches associated with the monolayer
(19,20). The solid domains jam together, and the surface
viscosity increases by orders of magnitude, increasing the
resistance to surface tension gradient induced ﬂow (13).
SP-C increases the surface viscosity by almost an order of
magnitude as compared to lipid monolayers of the same lipid
composition. In addition to enhancing jamming, the hydro-
phobic helical part of SP-C stitches adjacent monolayers
together, leading to a higher surface viscosity (19,20). At
the higher surface tensions that accompany inhalation, the
ﬂuid phase lipids are reincorporated into the monolayer, and
the monolayer viscosity decreases, allowing the ﬁlm to be
adsorbed or respread and cover the increased alveolar sur-
face (2).
The lung surfactant ﬁlm mechanical properties at coexis-
tence are the two-dimensional analog of a three-dimensional
suspension of solids in a liquid (13,21). In three-dimensional
suspensions, as the solid volume fraction, f, approaches the
volume fraction for random close packing, fc, the viscosity
diverges as h ¼ ho(1 f=fc)a; where h is the steady-
shear viscosity of the dispersion, ho is the viscosity of the
suspending liquid, and the exponent, a, varies from 1 to 2
depending on the interactions between the solids (22). The
surface viscosity of lipid monolayers at coexistence for
a variety of compositions, surface pressures, and temper-
atures diverges in a similar fashion: hs ¼ hso(1 A=Ac)1;
where hso is the surface viscosity of the continuous, ﬂuid
phase, and hs is the effective surface viscosity of the mono-
layer (13). A is the area fraction of the solid phase, and Ac is
a critical solid phase fraction at which the solid domains jam
into each other and the viscosity diverges. Relatively small
changes in the ﬂuid/solid ratio can lead to order of magnitude
changes in the surface viscosity near Ac (13). By adding or
subtracting ﬂuid phase lipids from the monolayer in
a reversible fashion, the lung surfactant protein SP-C leads
to the divergence of the surface viscosity of the monolayers
at the appropriate surface tension to dramatically increase the
ﬂow resistance of surfactant from the alveoli.
This molecular picture may explain other macroscopic
aspects of lung mechanics. SP-C knockout mice show
reduced lung viscoelasticity in comparison to normal mice;
the higher monolayer viscosity in the presence of SP-C may
stabilize the alveoli against collapse at end expiration
(23,24). The viscosity-regulating function of SP-C can be
partially replaced by SP-B, but SP-B does not pull as much
ﬂuid phase from the monolayer as SP-C, nor does it have the
ability to bind monolayers together (20,25). This may
explain why SP-C knockout mice survive (23,24) but are
more susceptible to disease (24) or lung injury (26), espe-
cially when SP-B is depleted. Birds, whose lungs consist of
rigid tubular air capillaries that do not change volume or
surface area, have no SP-C (27).
EXPERIMENTAL
Materials
Dipalmitoylphosphatidylcholine (DPPC) and palmitoyloleoylphosphatidyl-
glycerol (POPG) were purchased from Avanti Polar Lipids (Alabaster, AL;
purity.99%) and palmitic acid (PA) from Sigma Chemical (St Louis, MO;
purity .99%). The lipids were mixed in weight ratios of 68:22:8 in 3:1
chloroform/methanol. This lipid mixture is chosen to mimic the functional
properties of natural lung surfactants both in vitro and in vivo (28) and is
similar to the clinically used replacement lung surfactant, Survanta. How-
ever, the composition of native surfactant varies signiﬁcantly from species to
species, and the compositions of replacement surfactants vary even more due
to difﬁculties in extraction and in the number and type of additives used, so
there is no universally accepted surfactant composition (29). Peptide mimics
of the lung surfactant proteins SP-B and SP-C were synthesized as described
elsewhere (20) and added to the lipid mixture in 3:1 chloroform/methanol.
Water was prepared using a Millipore Milli-Q system and had a resistivity
.18 MV-cm1.
Survanta is an organic solvent extract of minced bovine lungs produced
for clinical use by Ross Laboratories (Columbus, OH). After extraction,
Survanta contains mainly phospholipids, neutral lipids, fatty acids, and
two surfactant speciﬁc proteins, SP-B and SP-C (29). The extract is then
supplemented with synthetic DPPC, PA, and tripalmitin to standardize the
Survanta composition and optimize its in vitro performance. The resulting
formulation contains ;70% DPPC and other saturated phospholipids and
10% fatty acids, mainly PA. There is,1% (by weight) of surfactant protein,
which is primarily SP-C. Survanta is sold and used as an aqueous suspension
in physiological saline with a concentration of 25 mg/ml phospholipids. For
our experiments, Survanta was diluted in buffer (NaCl 150 mM, CaCl2
2 mM, NaHCO3 0.2 mM, and pH ¼ 7) to a lipid concentration of 1 or
2 mg/ml and was spread onto the same buffer solution in the Langmuir
trough. Typically, sufﬁcient Survanta was added to raise the surface pressure
to ;10 mN/m before compression was initiated.
Curosurf (Chiesi Farmaceutici, Parma, Italy) is an organic extract of
porcine lungs and contains 50%–65% saturated phosphatidylcholines,
mainly DPPC (29). Curosurf contains both SP-B and SP-C but has minimal
free fatty acids. Curosurf was also diluted in buffer (NaCl 150 mM, CaCl2
2 mM, NaHCO3 0.2 mM, and pH ¼ 7) to a lipid concentration of 1 or
2 mg/ml and was spread onto the same buffer solution in the Langmuir
trough. Sufﬁcient Curosurf was added to raise the surface pressure to
;10 mN/m before compression was initiated.
Methods
Pressure-area isotherms were collected using a custom built Langmuir
trough with a Wilhelmy-type pressure-measuring device and a computer-
controlled barrier. The model monolayers were spread dropwise from the 3:1
chloroform/methanol solvent with Hamilton syringes (;0.5 mg/ml) onto
ultra pure water for protein free mixtures (MilliQ, 18.3mV.cm) or onto
saline buffer (150 mMNaCl, 2 mMCaCl2, 0.2 mMNaHCO3) at pH¼ 7.06
0.1 for samples with proteins. The initial compressions were begun after
;10 min to allow for complete evaporation of the solvent. Survanta and
Curosurf were spread as aqueous suspensions by syringe; sufﬁcient sur-
factant was added to the trough to obtain a surface pressure of ;10 mN/m
at full trough expansion. For ﬂuorescence imaging, the lipid mixtures were
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doped with 0.5–1 mol % of the ﬂuorescent lipid Texas Red-DHPE
(Molecular Probes, Eugene, OR). The ﬂuorescent probe segregates to dis-
ordered or ﬂuid phases, which then appear bright in images. The probe is
absent from the solid or liquid condensed (LC) phases, which appear black
or dark (17). The ﬂuorescence imaging system is described elsewhere (20).
Magnetic needle viscometer
The steady-shear surface viscosity was measured in a custom built magnetic
needle viscometer (21). To achieve a constant force on the magnetic needle
(Fm), the trough was positioned off-center between two Helmholtz coils
(21). A 14 mm wide channel formed by two glass plates was made along the
axis of the magnetic gradient within which a magnetic needle (a Teﬂon rod
3 cm long and 2 mm diameter) was ﬂoated. The amplitude of the magnetic
force, Fm, was adjusted by varying the current in the coils via two power
supplies. Above the channel, a video camera recorded the needle motion.
The video signal was then digitized and the needle speed derived from these
images (13,14,21). The absolute drag on the needle was determined from the
initial and terminal velocity of the needle and calibrated to known DPPC
surface shear viscosity (13,14,21). The density of the needle is greater than
that of water, so the needle typically sinks at;50 mN/m; the surface tension
of the interface is not high enough to keep the needle ﬂoating. Hence, we
cannot measure the surface viscosity over the entire physiologically rele-
vant range of 40–72 mN/m. Each viscosity measurement was performed at a
ﬁxed surface pressure and temperature and was repeated a minimum of three
times.
Atomic force microscopy
Selected ﬁlms were transferred to mica substrates for atomic force micros-
copy (AFM) imaging using a custom built transfer system (30). A modiﬁed
Nanoscope III FM (Digital Instruments, Santa Barbara, CA) was used for
imaging. A low-resolution ﬂuorescence optical microscope was used to
position the AFM tip onto speciﬁc regions of the sample. Once the desired
regions were located, AFM imaging was done with a 150 mm3 150 mm (J)
scanner in contact mode. Silicon nitride tips with a spring constant of
0.12 N/m were used. Exerting large forces on the sample was a concern
during imaging, so samples were checked often for deformation. This was
done by imaging for a few minutes on a smaller region (;20 mm), then
zooming out to check if damage had been done to the scanned region.
RESULTS AND DISCUSSION
The surface viscosities of individual lipids and mixtures com-
mon to lung surfactants (29) measured with a custom de-
signed magnetic needle viscometer (13,14,21) are shown in
Fig. 1. POPG is always in the liquid expanded (LE) phase at
physiological conditions and is representative of the un-
saturated lipids in lung surfactant (31). The surface viscosity
of POPG remains ,0.001 mN-s/m over the entire range of
surface pressure. In contrast, the viscosity of PA increases
suddenly at p ¼ 22 mN/m. PA monolayers have a crystalline
packing with the molecules in a tilted herringbone motif
(L299 phase) below 22 mN/m. Above 22 mN/m, the lattice is
untilted (32,33) and hs jumps by almost an order of mag-
nitude. The viscosity is correlated with the longer correlation
lengths and tighter grain boundaries in the untilted phase
(32,33), even though the probe used to measure viscosity is
macroscopic (14).
DPPC, the dominant lipid in native lung surfactant,
undergoes a LE to LC ﬁrst order transition at 12 mN/m at
25C; the coexistence pressure increases with increasing
temperature (34,35). In the LE phase, the viscosity is ;.001
mN-s/m, similar to POPG. In the LC phase, the viscosity
increases exponentially with surface pressure (8,14). DPPC/
POPG (68:22 wt/wt) mixtures exhibit coexistence between
a DPPC-rich LC phase and a POPG-rich LE phase (35) at
surface pressures above ;10 mN/m (ﬂuorescence micro-
graphs inset to Fig.1). POPG inhibits the growth of the LC
domains without affecting the molecular packing (35),
causing the surface viscosity to decrease relative to pure
DPPC. Adding PA to the DPPC/POPG mixture (68:22:8 wt/
wt) leads to a signiﬁcant increase in both the fraction of solid
phase at a given surface pressure and the surface viscosity
(inset to Fig. 1). PA causes a decrease in the molecular tilt
and an increase in the molecular cohesion of DPPC crystals
(13,34). LC phase islands of cocrystallized DPPC and PA
(dark in images) coexist with a continuous DPPC/POPG
LE phase (bright; 13,35). hs increases with the area frac-
tion of solid, as can be seen by the comparison of the ﬂuo-
rescence images with and without PA (13). The size and
FIGURE 1 Surface shear viscosity, hs, as a function of surface pressure,
p, for Langmuir monolayers of POPG, PA, DPPC, DPPC/POPG 4:1, DPPC/
POPG/PA 68:22:8 (wt/wt) at 25C. The POPG monolayer remains in the
ﬂuid state at all p, thus hs remains low. The PA monolayer undergoes a
transition from a tilted to a nontilted phase at 22 mN/m, which triggers a
dramatic increase of hs. DPPC surface viscosity in the LE phase (below;15
mN/m) is similar to POPG. In the LC phase, hs increases exponentially.
Both DPPC/POPG (bottom inset image) and DPPC/POPG/PA (top inset
image) ﬁlms show coexistence between solid phase islands (black in inset
images) and a continuous ﬂuid phase (bright in inset images) for surface
pressures .10 mN/m. Both images shown are taken at 30 mN/m; PA
increases the fraction of solid phase at a given p, which also increases hs.
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polydispersity of the crystalline domains inﬂuences the
critical solid phase fraction at which the viscosity diverges,
Ac (13). The surface viscosity at coexistence is well de-
scribed by hs ¼ hso(1 A=Ac)1, and changes from the low
values of the continuous ﬂuid phase to that of the solid phase
as the solid domains jam into each other as the solid phase
fraction approaches Ac (13). At higher temperatures, the
transitions are shifted to higher surface pressures; the tran-
sition depends only on the solid phase area fraction and
Ac (13).
However, the maximum viscosity of the pure lipid ﬁlms is
;0.05 mN-s/m, which may be insufﬁcient to arrest surface
tension driven ﬂow or to help keep alveoli from collapsing at
the end of exhalation. Figs. 2 and 3 show that adding 5 wt %
of a synthetic version of lung surfactant speciﬁc protein SP-C
(SP-Cff; 18,20) increases the DPPC/POPG/PA surface
viscosity from ;.03 to .43 mN-s/m at p ¼ 45 mN/m, at
which the isotherm shows a plateau. This lipid mixture also
shows a strong hysteresis; on compression, the viscosity
stays low up to ;40 mN/m then increases by ;3 orders of
magnitude as the surface pressure is increased slightly. On
expansion, the viscosity decreases gradually with decreasing
surface pressure. Further increasing the SP-C concentration
to 15% does not change the surface viscosity signiﬁcantly.
Adding SP-C to pure POPG monolayers or other LE phase
monolayers (data not shown) does not increase the surface
viscosity; SP-C accentuates the percolation transition in
those ﬁlms that show a LE-LC coexistence (13).
The origin of the viscosity increase is made obvious by
AFM images of DPPC/POPG/PA ﬁlms with 2 wt % SP-Cff
transferred to mica substrates below (Fig. 4 A) and above
(Fig. 4 B) the plateau (19,20). The AFM images show that
below the plateau, the ﬂuid phase regions of the monolayer
are ;1 nm lower (darker in image, see height trace below)
than the solid phase regions. However, for the monolayers
transferred just above the plateau, where the dramatic change
in the viscosity is observed, the ﬂuid regions have thickened
to be ;5 nm higher than the solid phase domains. This is
consistent with the formation of three-layer thick areas in the
ﬂuid phase. The plateau in the isotherms of these ﬁlms (Fig.
2) is consistent with a loss of interfacial area corresponding
to the removal of ﬂuid phase lipids from the interface to form
these multilayer patches. The clinical surfactants Curosurf
and Survanta, which both contain native SP-C, also show
multilayer patches in the ﬂuid phases (15).
Native SP-C is a 4.2 kDa, dipalmitoylated, 35-residue
peptide, of which 23 residues are hydrophobic; both SP-C
(19,20) and SP-B (25,36,37) are primarily located in the ﬂuid
phase domains of the monolayer. SP-C has a transbilayer
orientation similar to that of integral membrane proteins and
adopts an a-helical conformation between residues 9 and 34
(18). The N-terminal segment includes two palmitoylcys-
teinyls. The length of the a-helix is ;3.7 nm and orients
along the acyl chains of lipids in a monolayer or bilayer
environment (18,38). Hence, it is likely that the multilayers
seen in Fig. 4 B are held together by the transmembrane SP-C
(19). Native SP-C, palmitoylated human recombinant SP-C,
and synthetic SP-Cff have similar effects in promoting the
monolayer to multilayer transition (19,20).
The p-A isotherms for DPPC/POPG/PA with various con-
centrations of dSP-B1-25, a peptide mimic of native SP-B, are
FIGURE 2 Surface-pressure-area isotherm of DPPC/POPG/PA (68:22:8
wt %) monolayers with varying weight fractions of SP-Cff. Adding SP-Cff
shifts the isotherms to larger area/molecule, showing that the protein has
incorporated into the interface. The pronounced plateau at ;40 mN/m
shows that the monolayer loses material or is strongly condensed. This is
consistent with the multilayer formation shown in Fig. 4.
FIGURE 3 Surface shear viscosity, hs, as a function of surface pressure,
p, for DPPC/POPG/PA (68:22:8 wt %) monolayers with varying weight
fractions of SP-Cff. The surface viscosity on compression remains low up to
;40 mN/m, at which it increases by more than three orders of magnitude.
On expansion, the surface viscosity decreases more slowly with decreasing
surface pressure, showing a marked hysteresis. Five percent SP-Cff increases
the surface viscosity by a factor of 5 over the lipid alone. Increasing the
SP-Cff to 15% provides only a marginal increase in the surface viscosity.
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shown in Fig. 5. At a given surface pressure, the average
area per molecule increases with the peptide concentration,
showing the insertion of the protein within the monolayer.
On all the isotherms, there is a smooth kink at low pressure
and a shallow plateau at higher pressures, which are dis-
placed toward lower pressures as the peptide concentration
increases. The plateau goes from ;40 mN/m for the pure
lipid ﬁlm to ;32 mN/m with 10% dSP-B1-25. The mono-
layers collapse at the same pressure, ;66 mN/m.
The corresponding surface viscositymeasurements (Fig. 6)
also show two regimes. For surface pressures below the
plateau, hs is low and almost constant, as is the case for ﬁlms
containing SP-C (Fig. 3). At the plateau surface pressure, the
FIGURE 4 AFM images of DPPC/POPG/PA 1
SP-Cff ﬁlms. (A) Below the plateau in the isotherm,
the ﬂuid phase regions are 1 nm lower (see height
trace) than the condensed regions. (B) Above the
plateau, the ﬂuid regions have thickened to be
;5 nm higher than the condensed domains. This is
consistent with the formation of three-layer thick
areas in the ﬂuid phase. The plateau in the iso-
therms corresponds to the removal of ﬂuid phase
lipids from the interface to form these multilayer
patches. SP-C acts to regulate the solid/ﬂuid phase
ratio causing the surface viscosity to diverge.
FIGURE 5 Pressure-area isotherms of 68:22:8 DPPC/POPG/PA lipid
mixture with various amounts of dSP-B1-25, a peptide mimic of native SP-B
(25). Increasing the dSP-B1-25 fraction moves the isotherms to the right,
indicating that the dSP-B1-25 is retained in the ﬁlm. The collapse pressure
stays the same.
FIGURE 6 Surface viscosity as a function of surface pressure for the
dSP-B1-25 containing ﬁlms. Increasing the dSP-B1-25 content to 5% only
increases the surface viscosity by ;50%, compared to more than a factor of
5 increase caused by an equal amount of SP-C. Increasing the dSP-B1-25
fraction increases the surface viscosity, suggesting that more ﬂuid phase
lipids are removed from the monolayer, consistent with the images in Fig. 7.
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surface viscosity increases; however, there is only about a
50% increase in the maximum hs value of the ﬁlm with 5%
dSP-B1-25 compared to the lipid-only mixture. This is com-
pared to the factor of 5 with the same amount of SP-C added
(Fig. 3). dSP-B1-25 also is primarily located in the ﬂuid phase
domains and also removes ﬂuid phase lipids from the mono-
layer on compression, but not nearly as efﬁciently as SP-C
(25). As can be seen in the AFM images in Fig. 7, dSP-B1-25
leads to the formation of isolated protrusions from the ﬂuid
phase at high surface pressure (25). With no dSP-B1-25 in
the ﬁlms (Fig. 7 A), the solid phases are smooth and slightly
higher (;0.5 nm) than the ﬂuid phase, which is mottled
light and dark gray. With 5 wt % dSP-B1-25 in the ﬁlm
(Fig. 7 B), small white protrusions emerge from the ﬂuid
phase domains, with height ranging from ;5 to 10 nm.
Increasing the dSP-B1-25 to 10 wt % increases the lateral
dimensions of the protrusions but not their density (Fig. 7 C).
dSP-B1-25 removes material from the ﬂuid phase, as does
SP-C, but the location and distribution of the material is
quite different. The effect on the surface viscosity is, as
expected, not as great. SP-B also does not have the ability to
link monolayers together as does the transmembrane SP-C
(15,19,20,31).
Fig. 8 shows that the clinically used replacement
surfactants, Survanta and Curosurf, have very similar surface
viscosity as does the lipid and SP-C mixture. Survanta is an
extract of bovine lung surfactant supplemented with DPPC
and PA, whereas Curosurf is an extract of porcine lungs (29).
Both clinical surfactants show a dramatic increase in surface
viscosity at ;40–45 mN/m, consistent with the SP-C in-
duced percolation of the solid phase fraction. As expected,
Survanta has a higher viscosity due to the increased DPPC
and PA content, which increases the solid phase fraction
at a given surface pressure (see Fig. 1). Increasing the tem-
perature of the Survanta ﬁlms just moves the transition to
a higher surface pressure, consistent with the temperature
dependence of the solid phase area fraction. (The Curosurf
transition at 37 is at too high a surface pressure for our
instrument to measure.) AFM images show that both
Survanta and Curosurf form multilayer patches in the ﬂuid
phase domains at high surface pressures (15).
CONCLUSIONS
Relating these dramatic changes in viscosity to their
physiological implications is not obvious, as the optimal
surface viscosity of a lung surfactant ﬁlm has not been
established. The in vivo function of SP-C is also open to
question. A further complication is that the surface viscosity
can only be measured over a part of the physiologically
relevant surface pressure range of 35–70 mN/m due to
limitations of the magnetic needle surface viscometer (21).
However, from our previous work and theoretical analyses
FIGURE 7 AFM images of lipid ﬁlms transferred to
mica substrates at p ¼ 40 mN/m. (A) 0 wt % dSP-B1-
25. With no dSP-B1-25, the solid phase is smooth and
slightly higher (;0.5 nm) than the ﬂuid phase, which is
mottled light and dark gray. (B) 5 wt % dSP-B1-25. As
is the case for SP-C, SP-B is located in the ﬂuid phase
domains. The solid phase domains remain smooth and
are free of protrusion. dSP-B1-25 leads to the formation
of isolated small protrusions from the ﬂuid phase
domains, with heights ranging from;510 nm. SP-B
removes ﬂuid phase lipids from the monolayer on
compression, but not nearly as efﬁciently as SP-C. (C) 10 wt % dSP-B1-25. Increasing the dSP-B1-25 to 10 wt % increases the lateral dimensions of the
protrusions but not their density. dSP-B1-25 removes material from the ﬂuid phase, as does SP-C, but the location and distribution of the material is quite
different, leading to a smaller effect on the surface viscosity.
FIGURE 8 Surface shear viscosity of Survanta (bovine lung extract sup-
plemented with DPPC and PA) and Curosurf (porcine lung extract) replace-
ment lung surfactants. Both show similar behavior to the lipid mixtures in
that the surface viscosity strongly increases at a surface pressure (our
magnetic needle surface viscometer can only measure up to ;50 mN/m)
corresponding to an SP-C induced percolation of the solid phase domains
in the monolayer. Survanta has a lower transition surface pressure than
Curosurf at 25C, as the added PA and DPPC in Survanta increase the solid
phase fraction as in Fig. 1 (inset). Raising the temperature of the Survanta
ﬁlm to 37 moves the transition to higher surface pressure, consistent with
the observation that the solid phase fraction is smaller at higher temperatures
(13,34). Raising the temperature of the Curosurf ﬁlm to 37 presumably
moves the transition to a surface pressure higher than could be measured
using the magnetic needle viscometer (data not shown).
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of the origin of the high surface viscosity (13,15), it is likely
that the surface viscosity increases further as the solid phase
fraction increases with surface pressure over the physiol-
ogical range up to monolayer collapse (15). Hence, the re-
sistance to surface tension driven ﬂow should continue to
remain high over the entire physiological range of surface
pressures.
That regulation of surface viscosity is an important role for
SP-C is consistent with recent observations of SP-C deﬁcient
animals. One strain of SP-C deﬁcient mice is viable at birth
and grows normally without apparent pulmonary abnormal-
ities (23) but develops pulmonary problems after 1 year of
age (24). The absence of SP-C decreases the hysteresivity,
which describes the mechanical coupling between energy
dissipative forces and tissue-elastic properties, consistent
with a decrease in the surface viscosity. Lower than normal
levels of SP-B in SP-C deﬁcient mice led to lung dysfunction
(24). This suggests that the function of SP-C can be carried
out to some extent by SP-B in otherwise normal lungs,
consistent with our observations that SP-B increases the
surface viscosity of monolayers, but not as much as SP-C. In
a different strain of SP-C deﬁcient mice, however, there were
more severe abnormalities in airway resistance, tissue damp-
ing, and hysteresivity, suggesting signiﬁcant changes in the
mechanics of the lung surfactant system. It was suggested
that differences in shear forces over time contributed to the
disruption of lung structure and function that were observed
in the SP-C deﬁcient mice (24). The control over surfactant
viscosity demonstrated by SP-C appears to be important to
the mechanics of normal lung function; a lack of SP-C leads
to lung damage over time (24).
The ability of SP-C to regulate surface viscosity may be
illustrative of a more generic biological control over the
mechanical properties of two-dimensional systems including
cell membranes (39,40). Recent two-photon and ﬂuores-
cence micrographs show that phase coexistence occurs in
lipid bilayers as well as monolayers (39,40). This has led to
speculation that lipid phase separation is responsible for
‘‘raft’’ formation with its implications for protein localiza-
tion and function in cell membranes. The shear viscosity of
ﬂuid phases in two dimensions is quite low; by comparison
the viscosity of condensed phases is very large. However, as
shown here, it is not necessary to undergo a complete phase
transition to switch from low to high viscosity due to the
jamming of the solid phase domains. The mechanical prop-
erties of bilayer membranes might be controlled by subtle
adjustments in the area ratios of a more viscous and a less
viscous phase. Large changes in the membrane properties
could thus be induced by relatively small changes in the
membrane composition or local environment. Proteins sim-
ilar to the lung surfactant speciﬁc SP-B or SP-C, which have
the ability to condense or remove unsaturated lipids, may
act to tune the solid/liquid phase ratio. The ability of cell
membranes to control local membrane phase separation
and, hence, the membrane mechanical properties may be
necessary for a variety of cell recognition and binding events
(39–41).
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